The exact mechanisms of a disease can often be poorly understood. When there is little understanding of the disease pathology, in vitro phenotypic assays may provide more insight than target-based screening alone. Phenotypic screening allows researchers to identify new chemical entities and biomarkers without prior knowledge, or bias, of the target(s) underlying the response. Equally important, phenotypic assays provide a systems-based approach to assess compound liability.
OUR HIGH CONTENT IMAGING EXPERTISE ENABLES THE DETECTION OF ROBUST PHENOTYPIC RESPONSES AND IS A POWERFUL ORTHOGONAL APPROACH TO TARGET-BASED SCREENING.
With a diverse portfolio consisting of our PD3D™, ImmunoPD3D and functional toxicity service platforms, cpo provides you with the phenotypic results you're looking for. Our phenomic expertise enables the detection of robust phenotypic responses and is a powerful orthogonal approach to target-based screening. With a diverse portfolio consisting of our PD3D™, TruCUE and functional toxicity service platforms, cpo provides you with the phenotypic results you're looking for.
The identification and use of predictive biomarker assays has become an integral part of the drug discovery and development process. cpo has broad expertise in biomarker identification and assay development across a range of tumor entities, including colon and breast cancer.
Capabilities span the identification and validation of biomarkers and the development of quantitative assays in primary cells and disease tissue, pharmacodynamic and disease models, and as efficacy and translational medicine markers in the clinic. Our experience includes the translation of biomarker assays for use in the clinic for several client projects.
- FACS analysis
- RPPA analysis
- Proteomic markers
- Genomic markers
- Phosphoprotein markers
- Epigenetic markers
FIELD OF INTEREST